Dianthus Therapeutics (DNTH) Competitors $15.70 -1.27 (-7.51%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. IBRX, BEAM, VCEL, MIRM, GMTX, EWTX, CNTA, KYMR, CGON, and DNLIShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include ImmunityBio (IBRX), Beam Therapeutics (BEAM), Vericel (VCEL), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), Edgewise Therapeutics (EWTX), Centessa Pharmaceuticals (CNTA), Kymera Therapeutics (KYMR), CG Oncology (CGON), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. ImmunityBio Beam Therapeutics Vericel Mirum Pharmaceuticals Gemini Therapeutics Edgewise Therapeutics Centessa Pharmaceuticals Kymera Therapeutics CG Oncology Denali Therapeutics ImmunityBio (NASDAQ:IBRX) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, community ranking, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Which has better earnings and valuation, IBRX or DNTH? Dianthus Therapeutics has lower revenue, but higher earnings than ImmunityBio. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.75M171.90-$583.20M-$0.63-4.71Dianthus Therapeutics$6.24M87.44-$43.56M-$2.60-6.53 Do analysts prefer IBRX or DNTH? ImmunityBio presently has a consensus price target of $12.19, indicating a potential upside of 310.35%. Dianthus Therapeutics has a consensus price target of $54.33, indicating a potential upside of 220.17%. Given ImmunityBio's higher possible upside, equities analysts clearly believe ImmunityBio is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Do insiders and institutionals have more ownership in IBRX or DNTH? 8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 83.4% of ImmunityBio shares are owned by company insiders. Comparatively, 16.6% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor IBRX or DNTH? Dianthus Therapeutics received 10 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 96.30% of users gave Dianthus Therapeutics an outperform vote while only 43.24% of users gave ImmunityBio an outperform vote. CompanyUnderperformOutperformImmunityBioOutperform Votes1643.24% Underperform Votes2156.76% Dianthus TherapeuticsOutperform Votes2696.30% Underperform Votes13.70% Is IBRX or DNTH more profitable? Dianthus Therapeutics has a net margin of -1,250.32% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-8,016.83% N/A -110.02% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Does the media favor IBRX or DNTH? In the previous week, ImmunityBio had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 8 mentions for ImmunityBio and 3 mentions for Dianthus Therapeutics. ImmunityBio's average media sentiment score of 0.48 beat Dianthus Therapeutics' score of 0.18 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, IBRX or DNTH? ImmunityBio has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. SummaryDianthus Therapeutics beats ImmunityBio on 10 of the 19 factors compared between the two stocks. Remove Ads Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$545.16M$6.73B$5.54B$7.50BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-6.796.9923.2418.07Price / Sales87.44198.60361.2586.83Price / CashN/A65.6738.1634.64Price / Book1.495.926.493.99Net Income-$43.56M$142.37M$3.21B$247.18M7 Day Performance-15.11%-7.24%-4.91%-4.25%1 Month Performance-14.55%-10.45%-0.08%-6.87%1 Year Performance-31.38%-14.58%6.40%-3.73% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.2709 of 5 stars$15.70-7.5%$54.33+246.2%-35.3%$490.07M$6.24M-6.1080Gap DownIBRXImmunityBio1.9303 of 5 stars$2.85+5.2%$12.19+327.6%-48.0%$2.43B$14.75M-3.10590Gap DownBEAMBeam Therapeutics3.0959 of 5 stars$24.01+3.0%$50.82+111.7%-44.5%$2.40B$63.52M-13.64510Insider TradeShort Interest ↑Positive NewsVCELVericel2.9033 of 5 stars$47.94+3.6%$62.29+29.9%-15.3%$2.40B$237.22M799.13300Positive NewsMIRMMirum Pharmaceuticals4.3131 of 5 stars$47.02flat$58.20+23.8%+74.7%$2.30B$336.89M-23.28140GMTXGemini TherapeuticsN/A$52.24-1.9%N/A+51.5%$2.26BN/A-52.2430Gap DownHigh Trading VolumeEWTXEdgewise Therapeutics1.8042 of 5 stars$23.37-1.0%$45.38+94.2%-26.6%$2.22BN/A-15.5860Analyst ForecastOptions VolumeNews CoverageGap DownCNTACentessa Pharmaceuticals2.81 of 5 stars$16.63+5.6%$26.00+56.3%+20.7%$2.19B$6.85M-10.87200Gap DownKYMRKymera Therapeutics1.2443 of 5 stars$33.70+3.6%$56.36+67.2%-36.2%$2.19B$47.07M-14.40170News CoverageGap DownCGONCG Oncology1.0922 of 5 stars$28.53+5.5%$63.88+123.9%-51.2%$2.17B$684,000.000.0061Analyst RevisionNews CoverageGap DownDNLIDenali Therapeutics4.1975 of 5 stars$14.76+2.3%$37.20+152.0%-34.0%$2.14B$330.53M-5.35430News CoverageGap Down Remove Ads Related Companies and Tools Related Companies ImmunityBio Alternatives Beam Therapeutics Alternatives Vericel Alternatives Mirum Pharmaceuticals Alternatives Gemini Therapeutics Alternatives Edgewise Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Kymera Therapeutics Alternatives CG Oncology Alternatives Denali Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
